Remission of an intracardiac melanoma metastasis after tremelimumab therapy.
Tremelimumab is a fully human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4. Administration of tremelimumab to patients with locally advanced and metastatic melanoma has resulted in a subset of patients with durable objective tumour regressions. Our echocardiographic images impressively show the effects of this new antibody in a patient with cardiac metastatic malignant melanoma.
Medizinische Klinik für Kardiologie und Angiologie, Campus Mitte, Charité - Universitätsmedizin, Berlin, Germany ; Bundeswehrkrankenhaus Berlin, Abteilung I - Innere Medizin, Berlin, Germany.
Sebastian
S
Spethmann
Dermatologikum Berlin, Berlin, Germany.
Uwe
U
Trefzer
Medizinische Klinik für Kardiologie und Angiologie, Campus Mitte, Charité - Universitätsmedizin, Berlin, Germany.
Fabian
F
Knebel
Intracardiac melanoma metastasis; Tremelimumab; Tumour regression